FOXP Inhibitor

Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase. Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity.

Epirubicin (4'-Epidoxorubicin), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase. Epirubicin inhibits DNA and RNA synthesis. Epirubicin is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity.

Peptide P60 is a FOXP3 inhibitor. Peptide P60 reduces the nuclear translocation of FOXP3 and impairs FOXP3-mediated inhibition of NF-κB and NFAT activity. Peptide P60 inhibits the immunosuppressive activity of regulatory T cells and restores the proliferation and activation of effector T cells. Peptide P60 induces lymphoproliferative autoimmune syndrome in neonatal ICR mice and reduces the number of CD4⁺CD25⁺Foxp3⁺ T cells in the spleen. Peptide P60 enhances the efficacy of AH1 (HY-P4193) peptide vaccine and recombinant adenovirus-based HCV NS3 vaccine in BALB/c mice, including protective effects against CT26 tumor implantation. Peptide P60 can be used in studies related to tumor immunity, viral infection and lymphoproliferative autoimmune syndrome.

Ertabresib (INCB-057643) is an orally active BET protein inhibitor. Ertabresib blocks gene transcription by targeting the BET protein family, induces cell cycle arrest and apoptosis by downregulating proto-oncogenes such as c-MYC, and additionally reduces the expression of FOXP3 and PD-L1 to improve the immune microenvironment. It also exerts synergistic effects and overcomes drug resistance when combined with chemotherapy and XPO1 inhibitors. Ertabresib can be used in research related to high-grade B-cell lymphoma with MYC and BCL2 rearrangements, pancreatic cancer, pancreatitis, and metastatic castration-resistant prostate cancer.

Pomalidomide-d₄ (CC-4047-d₄) is the deuterated-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

DS-437 is a dual PRMT5/7 inhibitor (IC₅₀s of PRMT5/7=6 μM). DS-437 is selective for PRMT5 and PRMT7 over 29 other human protein-, DNA-, and RNA-methyltransferases. DS-437 is a S-adenosylmethionine (SAM)-competitive inhibitor of PRMT5. DS-437 also inhibits DNMT3A and DNMT3B, with IC₅₀s of 52 and 62 μM, respectively. DS-437 inhibits the methylation of FOXP3.

CMD178 TFA is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits T_reg cell development.

AZD8701 (IONIS-1063734) is an antisense oligonucleotide targeting FOXP3 in regulatory T cells (Tregs), with a human IC₅₀ of 65.2 nM. AZD8701 binds to intronic sites of all FOXP3 pre-mRNA isoforms and mediates dose-dependent FOXP3 knockdown via free uptake. AZD8701 can be used in cancer-related research.

Pomalidomide (Standard) (CC-4047 (Standard)) is the analytical standard of Pomalidomide (HY-10984). This product is intended for research and analytical applications. Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

Alkyne-P60 is a potent 15-mer peptide inhibitor of Foxp3. Alkyne-P60 can bind with Foxp3, hinder its nuclear translocation, and diminish Foxp3-mediated inhibition of NFKB and NFAT functions. Alkyne-P60 is a ligand for target protein for PROTAC (HY-162943).

Pomalidomide-d₃ (CC-4047-d₃) is the deuterated-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

Epirubicin (hydrochloride) (Standard) is the analytical standard of Epirubicin (hydrochloride). This product is intended for research and analytical applications. Epirubicin hydrochloride (4'-Epidoxorubicin hydrochloride), a semisynthetic L-arabino derivative of doxorubicin, has an antineoplastic agent by inhibiting Topoisomerase. Epirubicin hydrochloride inhibits DNA and RNA synthesis. Epirubicin hydrochloride is a Forkhead box protein p3 (Foxp3) inhibitor and inhibits regulatory T cell activity.

Pomalidomide-¹⁵N,¹³C₅ (CC-4047-¹⁵N,¹³C₅) is the ¹³C, ¹⁵N-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

AZD8701 (IONIS-1063734) sodium is an antisense oligonucleotide targeting FOXP3 in regulatory T cells (Tregs). AZD8701 sodium can relieve immunosuppression in cancer.

Pomalidomide-¹³C₅ (CC-4047-¹³C₅) is the ¹³C-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

CMD178 is a lead peptide that consistently reduced the expression of Foxp3 and STAT5 induced by IL-2/s IL-2Rα signaling and inhibits T_reg cell development.

ES3-JFTN is an EGFR inhibitor. ES3-JFTN inhibits the TGF-β1/SMAD2 signaling pathway and downregulates FOXP3. Upon binding to EGFR, ES3-JFTN exhibits environment-sensitive turn-on fluorescence, enabling tumor-selective imaging, and mainly localizes to mitochondria in cells. ES3-JFTN inhibits tumor growth in a syngeneic mouse model of colon cancer. ES3-JFTN can be used for research on colon cancer.

Pomalidomide-d₅ (CC-4047-d₅) is the deuterated-labeled Pomalidomide (HY-10984). Pomalidomide (CC-4047) is an immunomodulatory agent. Pomalidomide downregulates TNF-alpha, IL-1, IL-11, and IL-12, upregulates IL-2, IL-5, and IL-10, and costimulates T cells. Pomalidomide inhibits the proliferation of T regulatory cells by reducing FOXP3/OX-40 expression and IL-2-mediated expansion. Pomalidomide inhibits CDK2/4/6 and p21^WAF-1, causing cell cycle arrest. Pomalidomide can be used in research on myelofibrosis-associated anemia, multiple myeloma, and colorectal cancer.

Ertabresib (Standard) (INCB-057643 (Standard)) is the analytical standard of Ertabresib (HY-111485). This product is intended for research and analytical applications. Ertabresib (INCB-057643) is an orally active BET protein inhibitor. Ertabresib blocks gene transcription by targeting the BET protein family, induces cell cycle arrest and apoptosis by downregulating proto-oncogenes such as c-MYC, and additionally reduces the expression of FOXP3 and PD-L1 to improve the immune microenvironment. It also exerts synergistic effects and overcomes drug resistance when combined with chemotherapy and XPO1 inhibitors. Ertabresib can be used in research related to high-grade B-cell lymphoma with MYC and BCL2 rearrangements, pancreatic cancer, pancreatitis, and metastatic castration-resistant prostate cancer.